?We have already shown that this new type of DNA vaccine is safe and can successfully activate the immune system in patients with prostate cancer, colon and lung. We believe that will prove useful for patients with acute leukemia and chronic leukemia.?Scientists believe they can control the disease by vaccinating patients against a gene associated with cancer , found ?expressed? in almost all acute and chronic leukemias.
A team of researchers and health professionals, led by Professor Christian Ottensmeyer, University of Southampton Experimental Medicine Cancer Center and Dr Katy Rezvani, Imperial College London and Imperial College Healthcare NHS Trust, ?We hope to recruit up to 180 patients in the study, which will take place in hospitals in Southampton, London and Exeter over the next two years.
A new treatment that strengthens the immune system of a patient and allows them to more effectively combat the disease is tested on patients for the first time in the United Kingdom.
Inovo CEO Dr. Joseph Kim, said: ?This study extends Inovo?s long relationship with the University of Southampton in an important disease area We?re proud that Inovo make a significant contribution to this phase II study for these tumors is not clearly met. Medical needs.?
The success of vaccines will be measured over a period of two years of survival for acute myeloid leukemia and to evaluate the immune response to the drug with a disease marker for chronic myeloid leukemia.
The DNA vaccine was developed at the University with funding for research and Leukemia & Lymphoma Cancer Research UK.
Quanterix Corporation, enabling a new generation of diagnostics based on a single array of Revolutionary molecule technology, announced that a significant increase in blood levels of beta amyloid 42 peptide, a component of plaques that are a feature, have been detected in patients undergoing hypoxia after cardiac arrest. Simoa ability to measure extremely low abundance proteins has led to the discovery of a direct link between brain injury caused by hypoxia and increased Abeta42 levels in the blood. The findings were presented April 12 at the American Academy of Neurology annual meeting held April 9 to 16 Honolulu, Hawaii.
The research is funded by the charity of leukemia and lymphoma research and evaluation of the efficacy and mechanism , a program that is funded by the Medical Research Council and managed by the National Institute for Health Research .
David Grant, scientific director of the Leukemia & Lymphoma Research, adds: ?We are delighted that this test will be to leukemia, is an important step for us to see the laboratory work on DNA vaccines that supported the organization to the next. logical step in clinical trials. The process has undergone extensive international peer review and we are very excited to see the first patients treated. We believe that this vaccine is real promise for improving outcomes in patients with leukemia. ?
The treatment is to use a DNA vaccine, developed by scientists at the University of Southampton, which will be a select group of volunteers who have chronic or acute myeloid ? two forms of cancer of the bone marrow and blood.
new york times square jaws first night ball drop dick clark new years eve brock lesnar vs alistair overeem times square new years eve
No comments:
Post a Comment